Logo image of DRRX

DURECT CORPORATION (DRRX) Stock Fundamental Analysis

NASDAQ:DRRX - Nasdaq - US2666055007 - Common Stock - Currency: USD

0.6257  -0.01 (-1.73%)

After market: 0.5903 -0.04 (-5.66%)

Fundamental Rating

3

Overall DRRX gets a fundamental rating of 3 out of 10. We evaluated DRRX against 194 industry peers in the Pharmaceuticals industry. The financial health of DRRX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, DRRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DRRX has reported negative net income.
In the past year DRRX has reported a negative cash flow from operations.
In the past 5 years DRRX always reported negative net income.
In the past 5 years DRRX always reported negative operating cash flow.
DRRX Yearly Net Income VS EBIT VS OCF VS FCFDRRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -34.21%, DRRX perfoms like the industry average, outperforming 48.72% of the companies in the same industry.
DRRX has a Return On Equity (-91.81%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -34.21%
ROE -91.81%
ROIC N/A
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
DRRX Yearly ROA, ROE, ROICDRRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Gross Margin of DRRX (40.32%) is better than 61.03% of its industry peers.
In the last couple of years the Gross Margin of DRRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for DRRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 40.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
DRRX Yearly Profit, Operating, Gross MarginsDRRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

DRRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DRRX has been increased compared to 1 year ago.
DRRX has more shares outstanding than it did 5 years ago.
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DRRX Yearly Shares OutstandingDRRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DRRX Yearly Total Debt VS Total AssetsDRRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -60.83, we must say that DRRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -60.83, DRRX is doing worse than 92.82% of the companies in the same industry.
There is no outstanding debt for DRRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -60.83
ROIC/WACCN/A
WACC12.24%
DRRX Yearly LT Debt VS Equity VS FCFDRRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

DRRX has a Current Ratio of 1.23. This is a normal value and indicates that DRRX is financially healthy and should not expect problems in meeting its short term obligations.
DRRX has a Current ratio of 1.23. This is in the lower half of the industry: DRRX underperforms 78.97% of its industry peers.
DRRX has a Quick Ratio of 1.22. This is a normal value and indicates that DRRX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.22, DRRX is not doing good in the industry: 69.23% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.22
DRRX Yearly Current Assets VS Current LiabilitesDRRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

DRRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.52%, which is quite impressive.
Looking at the last year, DRRX shows a very negative growth in Revenue. The Revenue has decreased by -41.75% in the last year.
The Revenue for DRRX have been decreasing by -39.51% on average. This is quite bad
EPS 1Y (TTM)83.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
Revenue 1Y (TTM)-41.75%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-82.43%

3.2 Future

The Earnings Per Share is expected to grow by 60.95% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 53.91% on average over the next years. This is a very strong growth
EPS Next Y-105.89%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue Next Year-92.31%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DRRX Yearly Revenue VS EstimatesDRRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
DRRX Yearly EPS VS EstimatesDRRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRRX Price Earnings VS Forward Price EarningsDRRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRRX Per share dataDRRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

DRRX's earnings are expected to grow with 57.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.45%
EPS Next 3Y57.26%

More info and screens

0

5. Dividend

5.1 Amount

DRRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DURECT CORPORATION

NASDAQ:DRRX (7/11/2025, 8:06:01 PM)

After market: 0.5903 -0.04 (-5.66%)

0.6257

-0.01 (-1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-05 2025-08-05
Inst Owners22.3%
Inst Owner Change0%
Ins Owners11.21%
Ins Owner Change0%
Market Cap19.42M
Analysts80
Price Target5.1 (715.09%)
Short Float %2.92%
Short Ratio6.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)751.12%
Min EPS beat(2)-9.24%
Max EPS beat(2)1511.48%
EPS beat(4)3
Avg EPS beat(4)388.46%
Min EPS beat(4)-9.24%
Max EPS beat(4)1511.48%
EPS beat(8)6
Avg EPS beat(8)212.44%
EPS beat(12)9
Avg EPS beat(12)143.92%
EPS beat(16)13
Avg EPS beat(16)112.24%
Revenue beat(2)1
Avg Revenue beat(2)-37.45%
Min Revenue beat(2)-82.8%
Max Revenue beat(2)7.9%
Revenue beat(4)1
Avg Revenue beat(4)-23.47%
Min Revenue beat(4)-82.8%
Max Revenue beat(4)7.9%
Revenue beat(8)2
Avg Revenue beat(8)-22.97%
Revenue beat(12)2
Avg Revenue beat(12)-23.09%
Revenue beat(16)4
Avg Revenue beat(16)-5.19%
PT rev (1m)-25.93%
PT rev (3m)-25.93%
EPS NQ rev (1m)7.69%
EPS NQ rev (3m)7.69%
EPS NY rev (1m)4.94%
EPS NY rev (3m)-4.81%
Revenue NQ rev (1m)50%
Revenue NQ rev (3m)-68.21%
Revenue NY rev (1m)49.94%
Revenue NY rev (3m)29.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.01
P/FCF N/A
P/OCF N/A
P/B 3.63
P/tB 7.4
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.16
BVpS0.17
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.21%
ROE -91.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 40.32%
FCFM N/A
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.22
Altman-Z -60.83
F-Score4
WACC12.24%
ROIC/WACCN/A
Cap/Depr(3y)86.47%
Cap/Depr(5y)78.99%
Cap/Sales(3y)0.86%
Cap/Sales(5y)0.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
EPS Next Y-105.89%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue 1Y (TTM)-41.75%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-82.43%
Revenue Next Year-92.31%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%
EBIT growth 1Y45.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.08%
OCF growth 3YN/A
OCF growth 5YN/A